Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Sales (2020 - 2025)

Historic Return on Sales for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 0.47%.

  • Apellis Pharmaceuticals' Return on Sales rose 7600.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.04%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 0.25% for FY2024, which is 10800.0% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Return on Sales is 0.47%, which was up 7600.0% from 0.24% recorded in Q2 2025.
  • Apellis Pharmaceuticals' Return on Sales' 5-year high stood at 0.47% during Q3 2025, with a 5-year trough of 351.83% in Q2 2021.
  • Moreover, its 5-year median value for Return on Sales was 1.29% (2023), whereas its average is 22.84%.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -269100bps in 2021, then surged by 3422800bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Return on Sales (Quarter) stood at 2.45% in 2021, then tumbled by -199bps to 7.32% in 2022, then skyrocketed by 92bps to 0.61% in 2023, then soared by 72bps to 0.17% in 2024, then skyrocketed by 375bps to 0.47% in 2025.
  • Its Return on Sales was 0.47% in Q3 2025, compared to 0.24% in Q2 2025 and 0.55% in Q1 2025.